Feed/Companies/Triana Biomedicines

Triana Biomedicines

As of 14 Oct 2026, Triana Biomedicines has raised $120M across 1 verified round on record; latest: $120 million Series B led by Ascenta Capital and Bessemer Venture Partners, announced 3 Dec 2025.

BUILT ON

Visit site

Trianabio sells novel biopharmaceutical therapeutics focused on utilizing molecular glues to treat previously undruggable diseases, primarily targeting cancer.

trianabio.comLinkedInLexington, MA

LATEST ROUND

Series B

$120M · 2025-12-03

RAISED ON RECORD · USD

$120M

across 1 verified round

INVESTORS

2 leads

SOURCES

from 2 publishers

Feed/Companies

Company

Every round on record, with the sources behind each and the investors on them.

BUILT ON

Series B

$120M · 2025-12-03

[ HISTORY ]

led by Ascenta Capital, Bessemer Venture Partners

Round	Amount	Announced	Lead	Buzz
Series B [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it.	$120M	2025-12-03	Ascenta Capital, Bessemer Venture Partners	No recent discussion
2 sources [ VERIFIED · CORRECTED ] read against 2 sources

Triana Biomedicines

Company

Rounds

Sources

Profile

Investors

Triana Biomedicines

Rounds

Profile

Sources

Series B$120M2025-12-032 sources

Investors

Series B$120M2025-12-0311 investors